News

21 Sep 2022

Epimune's clinical partners at Stanford University publish new study on epigenetic immune cell quantification of regulatory T-cells (Treg) in patients with IPEX (Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked) Syndrome.

12 July 2022

Epimune wins important regulatory milestones for i.Mune TBNK® [CE] in Peru, Ecuador and Malaysia

25 May 2022

Epimune launches i.Mune® NEO (CE) - for the quantification of lymphocyte subsets in dried blood spot samples from newborns.  

11 Mar 2022

Epimune launches i.Mune® HOME (CE)

For the collection of a dried blood sample from the finger-tip.

 

27 Aug 2021

Epimune receives funding from German Ministry of Education and Research for the development of its i.Mune NEO test for early detection of inborn errors of immunity in newborns.

09 Aug 2021

New Article on using Epimune's epigenetic immune cell quantification as a second-tier test to reduce non-actionable secondary findings and false positive referrals in newborn screening for severe combined immunodeficiency published in Journal of Clinical Immunology

14 Apr 2021

Epimune's clinical collaborators at the The Center for Chronic Immunodeficiency (CCI) of the Medical Center - University of Freiburg (Germany) and the Leiden University Medical Center (Netherlands) are presenting their data using Epimune's epigenetic immune cell quantification technology at the 2021 CIS Virtual Annual Meeting.

29 Jan 2021

WHO includes lymphocyte subset enumeration tests in its Essential Diagnostics list (EDL)

(from: https://ipopi.org)

27 Jan 2021

Epimune GmbH and Tanner Pharma Group enter into Distribution Partnership for Latin America

26 Jan 2021

Epimune's collaborators at Leiden University Medical Center (LUMC) to present data on epigenetic immune cell quantification as a second tier test in SCID newborn screening at the ISNS-UKNSLN SCID meeting (26/27 Jan 2021; online)

11 Jan 2021

Epimune's collaborators at Leiden University Medical Center (LUMC) nominated for ZonMW Medical Inspirator Award 2020.